Glimepirid Al

Glimepirid Al is a prescription medication that contains the active ingredient glimepiride, a second‑generation sulfonylurea oral tablet (strength may vary). It is marketed in the European Union and is used as an oral hypoglycemic agent for managing blood glucose levels in adults with type 2 diabetes mellitus.

Glimepirid Al is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive diabetes management plan. It is typically used when diet, exercise, and other oral agents are insufficient to achieve glycemic control.

- Improves fasting and post‑prandial blood glucose levels. - Can be combined with metformin or other antidiabetic agents. - May be prescribed when lifestyle modifications alone do not maintain target HbA1c. - Used in adults with established type 2 diabetes. - Supports overall glycemic management alongside diet and exercise.

Glimepirid Al may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require medical attention.

Common: - Hypoglycemia (low blood sugar) - Weight gain - Nausea or abdominal discomfort - Headache - Dizziness - Skin rash or itching

Serious: - Severe hypoglycemia leading to loss of consciousness - Allergic reactions such as angioedema or anaphylaxis - Hepatic dysfunction - Hematologic abnormalities (e.g., leukopenia)

Before starting Glimepirid Al, certain precautions should be considered to ensure safe use. Patients should discuss their medical history and current conditions with a healthcare professional.

- Assess renal and hepatic function prior to initiation. - Use caution in elderly patients who may be more prone to hypoglycemia. - Monitor blood glucose regularly to adjust dosage as needed. - Avoid use during pregnancy and breastfeeding unless clearly indicated. - Discontinue if signs of severe hypoglycemia occur. - Review any history of cardiovascular disease or arrhythmias.

Glimepirid Al can interact with several medications, affecting its efficacy or safety profile. Some drug combinations should be avoided, while others require careful monitoring.

Avoid: - Other sulfonylureas or insulin secretagogues (risk of additive hypoglycemia). - Strong CYP2C9 inhibitors such as fluconazole or amiodarone (may increase glimepiride levels). - MAO inhibitors (potential for unpredictable blood glucose changes).

Use with caution: - Beta‑blockers (may mask hypoglycemia symptoms). - Thiazide diuretics (can affect glucose control). - Corticosteroids (may raise blood glucose, requiring dose adjustment). - Antifungal agents like itraconazole (moderate interaction).